Hannah Cohen

15.9k total citations · 3 hit papers
195 papers, 9.4k citations indexed

About

Hannah Cohen is a scholar working on Hematology, Rheumatology and Internal Medicine. According to data from OpenAlex, Hannah Cohen has authored 195 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hematology, 74 papers in Rheumatology and 35 papers in Internal Medicine. Recurrent topics in Hannah Cohen's work include Systemic Lupus Erythematosus Research (73 papers), Platelet Disorders and Treatments (43 papers) and Blood Coagulation and Thrombosis Mechanisms (38 papers). Hannah Cohen is often cited by papers focused on Systemic Lupus Erythematosus Research (73 papers), Platelet Disorders and Treatments (43 papers) and Blood Coagulation and Thrombosis Mechanisms (38 papers). Hannah Cohen collaborates with scholars based in United Kingdom, United States and Italy. Hannah Cohen's co-authors include Raj Rai, Samuel J. Machin, Ian Mackie, L. Regan, Manisha Dave, Barbara Panning, Chao Zhang, Kevan M. Shokat, Peter Walter and Douglas Yasumura and has published in prestigious journals such as Science, Blood and PLoS ONE.

In The Last Decade

Hannah Cohen

190 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response

2007 1.1k citations Jonathan H. Lin, Han Li et al. Science profile →
Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

1997 728 citations Hannah Cohen et al. profile →
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

2016 278 citations Hannah Cohen, Maria Efthymiou et al. profile →

Peers

Countries citing papers authored by Hannah Cohen

Since Specialization

Citations

This map shows the geographic impact of Hannah Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hannah Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hannah Cohen more than expected).

Fields of papers citing papers by Hannah Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hannah Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hannah Cohen. The network helps show where Hannah Cohen may publish in the future.

Co-authorship network of co-authors of Hannah Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Hannah Cohen. A scholar is included among the top collaborators of Hannah Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hannah Cohen. Hannah Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study 2024 ·Lupus ·(unknown), (unknown), (unknown), (unknown), (unknown), Hannah Cohen, Maria Efthymiou, David Isenberg	1
2	Sleep–wake behavior, perceived fatigability, and cognitive reserve in older adults 2024 ·Alzheimer s & Dementia ·Nancy Kerner, Terry E. Goldberg, Hannah Cohen, (unknown), Daniel E. Cohen, Howard Andrews, Gregory H. Pelton, Davangere P. Devanand	3
3	2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase–based antiphospholipid antibody domain—collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non–enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies 2024 ·Journal of Thrombosis and Haemostasis ·Pier Luigi Meroni, María Orietta Borghi, O Amengual, (unknown), María Laura Bertolaccini, Hannah Cohen, C. Grossi, Robert Roubey, Savino Sciascia, Anne E. Tebo, Rohan Willis, Doruk Erkan, Katrien Devreese	3
4	Can complement activation be the missing link in antiphospholipid syndrome? 2024 ·Lara D. Veeken ·(unknown), (unknown), (unknown), David Isenberg, Hannah Cohen, Maria Efthymiou	7
5	Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome 2024 ·Lara D. Veeken ·Maria Efthymiou, María Laura Bertolaccini, Hannah Cohen	1
6	Fluctuation of Anti–Domain 1 and Anti–β₂‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies 2023 ·Arthritis & Rheumatology ·Cecilia Beatrice Chighizola, Francesca Pregnolato, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz‐Irastorza, H. Michael Belmont, Maria Gerosa, Paul R. Fortin, D. Ware Branch, Laura Andréoli, Michelle Petri, Ricard Cervera, Jason S. Knight, Rohan Willis, Maria Efthymiou, Hannah Cohen, Doruk Erkan, María Laura Bertolaccini	12
7	The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome 2022 ·Lupus ·(unknown), (unknown), (unknown), Hannah Cohen	2
8	Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants 2021 ·Journal of Neurology Neurosurgery & Psychiatry ·David Seiffge, Duncan Wilson, Gareth Ambler, Gargi Banerjee, Isabel C. Hostettler, Henry Houlden, Clare Shakeshaft, Hannah Cohen, Tarek Yousry, Rustam Al‐Shahi Salman, Gregory Y.H. Lip, Martin M. Brown, Keith W. Muir, Hans Rolf Jäger, David J. Werring	26
9	Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage 2021 ·Neurology ·Isabel C. Hostettler, Ghil Schwarz, Gareth Ambler, Duncan Wilson, Gargi Banerjee, David Seiffge, Clare Shakeshaft, (unknown), Hannah Cohen, Tarek Yousry, Rustam Al‐Shahi Salman, Gregory Y.H. Lip, Martin M. Brown, Keith W. Muir, Henry Houlden, Hans Rolf Jäger, David J. Werring, (unknown)	14
10	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm 2021 ·Lupus ·(unknown), (unknown), Maria Efthymiou, Jonathan Lambert, Hannah Cohen	2
11	Longer term stroke risk in intracerebral haemorrhage survivors 2020 ·Journal of Neurology Neurosurgery & Psychiatry ·Gargi Banerjee, Duncan Wilson, Gareth Ambler, Isabel C. Hostettler, Clare Shakeshaft, Hannah Cohen, Tarek Yousry, Rustam Al‐Shahi Salman, Gregory Y.H. Lip, Henry Houlden, Keith W. Muir, Martin M. Brown, Hans Rolf Jäger, David J. Werring	14
12	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome 2020 ·Blood ·Hannah Cohen, David Isenberg	18
13	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis 2020 ·Journal of Thrombosis and Haemostasis ·Katrien Devreese, Philip G. de Groot, Bas de Laat, Doruk Erkan, Emmanuel J. Favaloro, Ian Mackie, Marta Martinuzzo, Thomas L. Ortel, Vittorio Pengo, Jacob H. Rand, Armando Tripodi, Denis Wahl, Hannah Cohen	245
14	The prevalence of incidental uterine venous plexus thrombosis in women attending a gynecology clinic 2020 ·Journal of Thrombosis and Haemostasis ·(unknown), Hannah Cohen, Michael L. Wong, (unknown), (unknown), D. Jurkovic	8
15	RAPS: a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE 2013 ·UCL Discovery (University College London) ·Hannah Cohen, Caroline J Doré, (unknown), Benjamin A.E. Hunt, Munther A. Khamashta, (unknown), Nicola Muirhead	1
16	Erratum: Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma (Transfusion (2009) 49 (440-452)) 2011 ·UCL Discovery (University College London) ·(unknown), (unknown), Hayley E Jones, (unknown), Edwin Massey, Nay Win, Cristina Navarrete, (unknown), N. Soni, (unknown), Louise Choo, Hannah Cohen, (unknown)	1
17	IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response breakdown → 2007 ·Science ·Jonathan H. Lin, Han Li, Douglas Yasumura, Hannah Cohen, Chao Zhang, Barbara Panning, Kevan M. Shokat, Matthew M. LaVail, Peter Walter	1140
18	Transfusion guidelines for neonates and older children 2004 ·British Journal of Haematology ·Brenda Gibson, Audrey Todd, Irene Roberts, Derwood Pamphilon, Charles Rodeck, Paula Bolton‐Maggs, (unknown), J Duguid, Frank Boulton, Hannah Cohen, Norm D. Smith, D. B. L. McClelland, Megan Rowley, G Turner, (unknown)	229
19	The Serious Hazards of Transfusion (SHOT) Initiative: The UK Approach to Haemovigilance 2000 ·Vox Sanguinis ·Lorna M. Williamson, Hannah Cohen, Elizabeth M. Love, Hilary Jones, Audrey Todd, Kate Soldan	48
20	A COMPARISON OF THE EFFECTS OF 2 TRIPHASIC ORAL-CONTRACEPTIVES ON HEMOSTASIS 1988 ·UCL Discovery (University College London) ·Hannah Cohen, IJ Mackie, (unknown), (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact